Targeting head and neck cancer epigenetics with CRISPR-dCas9: An emerging therapeutic approach.
Oral oncology, 127: 105801 PMID 35255281 DOI 10.1016/j.oraloncology.2022.105801
Abstract
This article has no abstract in PubMed.
Your browser does not allow saving data (e.g. private mode): bookmarks will be lost when the tab closes.